Comerica Bank
IMDX

Comerica Bank’s Insight Molecular Diagnostics IMDX Stock Holding History

Comerica Bank’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23
Closed -$67 – 3781
2024
Q1 		$67 Sell
23
-1
-4% -$3 ﹤0.01% 3725
2023
Q4 		$60 Sell
24
-13
-35% -$40 ﹤0.01% 3712
2023
Q3 		$116 Buy
+37
New +$138 ﹤0.01% 3771

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Comerica Bank's IMDX Position: Q2 2024 in Review

Comerica Bank sold out of Insight Molecular Diagnostics (IMDX) in Q2 2024, closing a stake of 23 shares — an estimated $67 sold.

Comerica Bank first reported a position in IMDX in Q3 2023 and held it in 3 quarters. The position peaked at $116 in Q3 2023. 23 funds tracked by Wall St. Rank hold IMDX as of Q2 2024.

  • Comerica Bank reported no remaining Insight Molecular Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Comerica Bank sold 23 Insight Molecular Diagnostics shares in Q2 2024, an estimated $67.
  • Comerica Bank first reported a position in Insight Molecular Diagnostics in Q3 2023 and held it in 3 quarters.
  • Comerica Bank's Insight Molecular Diagnostics position peaked at $116 in Q3 2023.
  • 23 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2024.

Based on Comerica Bank's 13F filing for Q2 2024, filed 15 Aug 2024.